Zantac Litigation – Timelines, Indemnification Dynamics & Settlement Scenario Outlook

  • Public Equity
  • Healthcare
  • Europe


Former general counsel at Teva Pharmaceutical Industries Ltd


  • Review of the scientific evidence supporting claimants’ cases and barriers to filing cases
  • Extent of the potential state and multidistrict litigation – filed vs unfiled lawsuits – and timelines following 22 August Illinois trial dismissal by the plaintiff
  • Zantac (ranitidine) ownership over previous years, relative exposure of different incumbents and indemnification mechanics
  • Teva (TLV: TEVA), Perrigo (NYSE: PRGO) and Sun Pharma (NSE: SUNPHARMA) settlement with one plaintiff and potential read-across to GSK (LON: GSK), who has reportedly not yet settled
  • Potential settlement scenarios


Gain access to Premium Content

Submit your details to access up to 5 Forum Transcripts or to request a complimentary one week trial.

    One week, unlimited access to over 40,000 transcripts
The information, material and content contained in this transcript (“Content”) is for information purposes only and does not constitute advice of any type or a trade recommendation and should not form the basis of any investment decision.This transcript has been edited by Third Bridge for ease of reading. Third Bridge Group Limited and its affiliates (together “Third Bridge”) make no representation and accept no liability for the Contentor for any errors, omissions or inaccuracies in respect of it. The views of the specialist expressed in the Content are those of the specialist and they are not endorsed by, nor do they represent the opinion of, Third Bridge. Third Bridge reserves all copyright, intellectual and other property rights in the Content. Any modification, reformatting, copying, displaying, distributing, transmitting, publishing, licensing, creating derivative works from, transferring or selling any Content is strictly prohibited